



10-25-02

AF
1614

Express Mail EV 011109508 US

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	09/856,987
Filing Date	05/25/2001
First Named Inventor	PANG
Group Art Unit	1614
Examiner Name	Fay, Z.
Attorney Docket Number	1719F US

Total Number of Pages in This Submission **4****ENCLOSURES (check all that apply)**

- | | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input checked="" type="checkbox"/> Amendment / Reply
<input checked="" type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application)
<input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Amended Claim Page
Return Card |
|--|---|--|

Remarks

RECEIVED
OCT 29 2002
TECH CENTER 1800/2900**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Sally S. Yeager Reg. 32,757
Signature	
Date	Oct 29, 2002

CERTIFICATE OF MAILINGI hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

In re Application of: PANG

Serial Number: 09/856,987

Filed: May 25, 2001

Examiner: Fay, Z.

Group Art Unit: 1614

FOR: USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT
OF OPHTHALMIC NEURODEGENERATIVE DISEASES

TECH CENTER 1600/2900

OCT 29 2002

RECEIVED

#7/B
(~~me~~)
JRP
11/4/02

AMENDMENT

Assistant Commissioner of Patents
Box AF
Washington, D.C. 20231

Sir:

This Amendment is filed in response to the Official Action mailed August 27, 2002.

Please amend the application as follows:

IN THE CLAIMS:

Please amend Claim 8 as follows:

8. A method for the treatment of retina or optic nerve head neuropathy associated with glaucoma which comprises administering to a mammal a composition comprising an effective amount of one or more neurotrophic factor stimulators and a pharmaceutically acceptable vehicle.

Pursuant to 37 C.F.R. 1.121(c)(1)(ii) a "marked-up" version of the amendment is attached to this Amendment.

REMARKS

Claim 8 has been amended; Claims 8 – 14 are pending.

Claims 8, 9, 11, and 12 have been rejected under 35 U.S.C. § 102(b) as being anticipated by Takeda Chem Ind., Ltd. for the reason set forth on page 2 of the Office Action